

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 April 2006 (20.04.2006)

PCT

(10) International Publication Number
WO 2006/040334 A1

(51) International Patent Classification:
A61K 39/015 (2006.01)

(74) Agents: KLEIN, Bart et al.; Crucell Holland B.V., c/o Archimedesweg 4, NL-2333 CN Leiden (NL).

(21) International Application Number:
PCT/EP2005/055209

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 13 October 2005 (13.10.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/619,056 14 October 2004 (14.10.2004) US
04105035.2 14 October 2004 (14.10.2004) EP

(71) Applicants (for all designated States except US): CRUCELL HOLLAND B.V. [NL/NL]; Archimedesweg 4, NL-2333 CN Leiden (NL). GLAXOSMITHKLINE BIOLOGICALS, S.A. [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE). WALTER REED ARMY INSTITUTE OF RESEARCH [US/US]; 503 Robert Grant Avenue, Silver Spring, Maryland 20910-7500 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

Declaration under Rule 4.17:

(75) Inventors/Applicants (for US only): PAU, Maria Grazia [IT/NL]; Bargelaan 80, NL-2333 CW Leiden (NL). GOUDSMIT, Jaap [NL/NL]; Koninginneweg 4, NL-1075 CX Amsterdam (NL). COHEN, Joseph, D. [US/BE]; GlaxoSmithKline, Rue de l'Institut 89, B-1330 Rixensart (BE). DUBOIS, Patrice, M. [BE/BE]; GlaxoSmithKline, Rue de l'Institut 89, B-1330 Rixensart (BE). STEWART, V. Ann [US/US]; 503 Robert Grant Avenue, Silver Spring, Maryland 20910-7500 (US). HEPPNER, Donald [US/US]; 503 Robert Grant Avenue, Silver Spring, Maryland 20910-7500 (US).

— of inventorship (Rule 4.17(iv))

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MALARIA PRIME/BOOST VACCINES

(57) Abstract: The invention relates to novel vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from Plasmodium falciparum and purified recombinant protein vaccines such as RTS,S, in the context of appropriate adjuvants.



WO 2006/040334 A1

TITLE

Malaria prime/boost vaccines

FIELD OF THE INVENTION

5 The invention relates to the field of medicine.
Specifically, the invention relates to novel prime/boost
vaccine strategies using recombinantly produced
adenoviral vectors and purified proteins in the context
of an adjuvant for the prevention of falciparum malaria.
10

BACKGROUND OF THE INVENTION

Malaria currently represents one of the most
prevalent infections in tropical and subtropical areas
throughout the world. Per year, malaria infections kill
15 up to 2.7 million people in developing and emerging
countries. The widespread occurrence and elevated
incidence of malaria are a consequence of the increasing
numbers of drug-resistant parasites and insecticide-
resistant parasite vectors. Other factors include
20 environmental and climatic changes, civil disturbances
and increased mobility of populations.

Malaria is caused by mosquito-borne hematoprotozoan
parasites belonging to the genus *Plasmodium*. Four species
of *Plasmodium* protozoa (*P.falciparum*, *P.vivax*, *P.ovale*
25 and *P.malariae*) are responsible for the disease in man;
many others cause disease in animals, such as *P.yoelii*
and *P.berghei*. *P.falciparum* accounts for the majority of
infections in humans and is the most lethal type. Malaria
parasites have a life cycle consisting of four separate
30 stages. Each one of these stages is able to induce
specific immune responses directed against the parasite
and the correspondingly occurring stage-specific
antigens, yet naturally induced malaria does not protect
against reinfection.

Malaria parasites are transmitted to man by several species of female *Anopheles* mosquitoes. Infected mosquitoes inject the sporozoite form of the malaria parasite into the mammalian bloodstream. Sporozoites remain for few minutes in the circulation before invading hepatocytes. At this stage the parasite is located in the extra-cellular environment and is exposed to antibody attack, mainly directed to the circumsporozoite (CS) protein, a major component of the sporozoite surface.

Once in the liver, the parasite replicates and develops into a schizont. During this stage, the invading parasite will undergo asexual multiplication, producing up to 20,000 daughter merozoites per infected cell. During this intra-cellular stage of the parasite, main players of the host immune response are T-lymphocytes, especially CD8+ T-lymphocytes (Romero et al. 1989). After about one week of liver infection, thousands of merozoites are released into the bloodstream and enter red blood cells (RBC's), becoming targets of antibody-mediated immune response and T-cell secreted cytokines. After invading the erythrocytes, the merozoites undergo several stages of replication, transforming into trophozoites, and schizonts, which rupture to produce a new generation of merozoites that subsequently infect new RBC's. The erythrocytic stage is associated with overt clinical disease. A smaller number of trophozoites may develop into male or female gametocytes, which are the parasite's sexual stage. When susceptible mosquitoes ingest gametocytes, the fertilization of these gametes leads to zygote formation and subsequent transformation into ookinetes, then into oocysts, and finally into sporozoites, which migrate to the salivary gland to complete the cycle.

The two major arms of the pathogen-specific immune response that occur upon entry of the parasite into the body are cellular and humoral. The one arm, the cellular response, relates to CD8+ and CD4+ T cells that participate in the immune response. Cytotoxic T lymphocytes (CTL's) express CD8 and are able to specifically kill infected cells that express pathogenic antigens on their surface. CD4+ T cells or T helper cells support the development of CTL's, produce various cytokines, and also help induce B cells to divide and produce antibodies specific for the antigens. During the humoral response, B cells specific for a particular antigen become activated, replicate, differentiate and produce antigen-specific antibodies.

Both arms of the immune response are relevant for protection against a malarial infection. When infectious sporozoites travel to the liver and enter the hepatocytes, the sporozoites become intracellular pathogens, spending little time outside the infected cells. At this stage, CD8+ T cells and CD4+ T cells are especially important because these T cells and their cytokine products, such as interferon- γ (IFN- γ), contribute to the killing of infected host hepatocytes. Elimination of the intracellular liver parasites in the murine malaria model is found to be dependent upon CD8+ T cell responses directed against peptides expressed by liver stage parasites (Hoffman and Doolan, 2000). Depletion of CD8+ T cells abrogates protection against sporozoite challenge, and adoptive transfer of CD8+ T cells to naïve animals confers protection.

When a malarial infection reaches the erythrocytic stage in which merozoites replicate in RBC's, the merozoites are also found circulating freely in the bloodstream. Because the erythrocyte does not express

either Class I or II MHC molecules required for cognate interaction with T cells, it is thought that antibody responses are most relevant at this stage. In conclusion, a possible malaria vaccine approach would be most
5 beneficial if it would induce a strong cellular immune response as well as a strong humoral immune response to tackle the different stages in which the parasite occurs in the human body.

10 Current approaches to malaria vaccine development can be classified according to the different developmental stages of the parasite, as described above. Three types of possible vaccines can be distinguished:

- 15 - Pre-erythrocytic vaccines, which are directed against sporozoites and/or schizont-infected hepatocytes. Historically, this approach has been dominated by (CS)-based strategies. Since the pre-erythrocytic phase of infection is asymptomatic, a pre-erythrocytic vaccine should ideally confer
20 sterile immunity, mediated by humoral and cellular immune response, and completely prevent latent malaria infection.
- Asexual blood stage vaccines, which are directed against either the infected RBC or the merozoite
25 itself, are designed to minimize clinical severity. These vaccines should reduce morbidity and mortality and are meant to prevent the parasite from entering and/or developing in the erythrocytes.
- Transmission-blocking vaccines, which are designed
30 to hamper the parasite development in the mosquito host. This type of vaccine should favor the reduction of population-wide malaria infection rates.

Finally, the feasibility of developing combination malaria vaccines that target multiple stages of the parasite life cycle is being pursued in so-called multi-component and/or multi-stage vaccines.

5 Currently no commercially available vaccine against malaria is available, although the development of vaccines against malaria was initiated more than 30 years ago. Immunization of rodents, non-human primates and humans with radiation-attenuated sporozoites conferred
10 protection against a subsequent challenge with viable sporozoites (Nussenzweig et al. 1967; Clyde et al. 1973). However, so far the expense and the lack of a feasible large-scale culture system for the production of irradiated sporozoites has prevented the widespread
15 application of such vaccines (Luke et al. 2003).

To date the most promising vaccine candidates tested in humans have been based on a small number of sporozoite surface antigens. The CS protein is the only *P.falciparum* antigen demonstrated to consistently prevent malaria when
20 used as the basis of active immunization in humans against mosquito-borne infection, albeit at levels that are often insufficient. Theoretical analysis has indicated that the vaccine coverage as well as the vaccine efficiency should be above 85%, or otherwise
25 mutants that are more virulent may escape in endemic areas (Gandon et al. 2001).

One way of inducing an immune response in a mammal is by administering an infectious vector, which harbors a nucleic acid encoding the antigen in its genome. One such
30 carrier is a recombinant adenovirus, which has been rendered replication-defective by removal of regions within the genome that are normally essential for replication, such as the E1 region. Examples of recombinant adenoviruses that comprise genes encoding

antigens are known in the art (WO 96/39178). For instance, HIV-derived antigenic components have been demonstrated to yield an immune response if delivered by recombinant adenoviruses (WO 01/02607; WO 02/22080; US 5 6,733,993). In malaria, recombinant adenovirus-based vaccines have been developed. These vectors express the entire CS protein of *P.yoelii*, one of the mouse malaria models, and these vectors have been shown to be capable of inducing sterile immunity in mice in response to a 10 single immunizing dose (Bruña-Romero et al. 2001). It has been demonstrated that CD8+ T cells primarily mediate this adenovirus-induced protection.

Since a high percentage of individuals have pre-existing immunity against the generally used adenoviral 15 vectors such as adenovirus serotype 5 (Ad5), new technologies were developed in the art, wherein recombinant replication-defective adenoviruses were based on serotypes that encountered pre-existing immunity in the form of neutralizing antibodies only in a small 20 percentage of healthy individuals. These serotypes are generally referred to as low-neutralized serotypes, or rare serotypes. It was found that Ad11, Ad24, Ad26, Ad34, Ad35, Ad48, Ad49 and Ad50 were particularly useful (WO 00/70071; WO 02/40665; WO 2004/037294; WO 2004/083418; 25 Vogels et al. 2003).

A DNA-based vaccine containing a plasmid that expresses the *P.falciparum* CS protein was developed by Vical, Inc. San Diego, CA, USA and the Naval Medical Research Center (Horn et al. 1995). Studies in a mouse 30 model demonstrated induction of antigen-specific CTL and antibody responses following immunization with plasmid DNA (Doolan et al. 1998). However, thus far the sole use of DNA vaccines have proved suboptimal for induction of protective immune responses in humans. Using the DNA

vaccine it was found that vaccinated volunteers did not develop antibodies against the CS protein as assessed by indirect fluorescent antibody test (IFAT) against air-dried sporozoites and ELISA against recombinant and synthetic peptides (Wang et al. 2001), although their CTL responses were significant.

In contrast, the RTS,S (purified protein) malaria vaccine approach (Gordon et al. 1995; US 6,306,625; WO 93/10152) is able to induce a robust antibody response to the CS protein (Kester et al. 2001; Stoute et al. 1997 and 1998), while it is also a potent inducer of Th1 type cellular and humoral immunity. Most importantly, this vaccine repeatably protects approximately half of the recipients. However, the protection elicited by RTS,S is of short duration (Stoute et al. 1998). Immunization with RTS,S induces anti-CS antibodies and CD4+ T cell-dependent IFN- γ responses, but poor CD8+ T cell-dependent CTL or IFN- γ responses (Lalvani et al. 1999). However, these minimal CD8+ responses that are produced have been demonstrated to correlate with protection in human trials (Sun et al. 2003). Thus, a rational improvement would focus on enhancement of the induction of CD8+ T cell responses to CS induced by RTS,S.

The challenge of developing a falciparum malaria vaccine that has a protective efficacy of at least 85% has not yet been met. The task is particularly difficult because, unlike with other often fatal diseases such as measles or smallpox, prior malaria exposure and the development of natural immunity is not protective against subsequent malaria infection. Of all vaccine candidates and vaccine delivery strategies tested to date, only RTS,S has consistently provided some level of protection. Other tested candidates have either been inadequately immunogenic, or immunogenic but inadequately protective.

This application describes a strategized combination of vaccine formulations designed to take advantage of the optimal serologic immunogenicity of the protein/adjuvant approach together with an excellent induction of cellular responses provided by recombinant replication-defective adenoviral vectors.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. Heterologous prime/boost vaccination regimens, followed by measuring the T cell response in IFN- γ ELISPOT analyses related to the C-terminus of CS. Response was measured two weeks after final boost. Horizontal bars represent geometric means.

Figure 2. T cell response measured in IFN- γ ELISPOT analyses related to the C-terminus of CS. Response was measured three months after final boost. Horizontal bars represent geometric means.

Figure 3. Antibody response measured in ELISA, related to the repeat region of CS, two weeks after boost. Horizontal bars represent geometric means.

Figure 4. Antibody response measured in ELISA, related to the repeat region of CS, three months after boost. Horizontal bars represent geometric means.

Figure 5. T cell response, in experiments priming with a recombinant Ad35-CS vector and boosting with RTS,S or Ad35-CS, measured by IFN- γ ELISpot after two weeks (left) or after three months (right). The homologous prime/boost/boost regimen RTS,S/RTS,S/RTS,S was used as a reference.

Figure 6. Antibody response, in experiments priming with a recombinant Ad35-CS vector and boosting with RTS,S or Ad35-CS, measured by ELISA after two weeks (left) or after three months (right). The homologous

prime/boost/boost regimen RTS,S/RTS,S/RTS,S was used as a reference.

Figure 7. T cell response, in experiments boosting with a recombinant Ad35-CS vector and priming with RTS,S or Ad5-
5 CS, measured after two weeks (left) or after three months (right). The homologous prime/boost/boost regimen RTS,S/RTS,S/RTS,S was used as a reference.

Figure 8. Antibody response, in experiments boosting with a recombinant Ad35-CS vector and priming with RTS,S or
10 Ad5-CS, measured after two weeks (left) or after three months (right). The homologous prime/boost/boost regimen RTS,S/RTS,S/RTS,S was used as a reference.

Figure 9. T cell response measured in IFN- γ ELISPOT analyses related to the N-terminus of CS, two weeks after
15 boost. Horizontal bars represent geometric means.

Figure 10. T cell response measured in IFN- γ ELISPOT analyses related to the N-terminus of CS, three months after boost. Horizontal bars represent geometric means.

Figure 11. T cell response to the N-terminus, in
20 experiments priming with a recombinant Ad35-CS vector and boosting with RTS,S or Ad35-CS, measured after two weeks (left) or after three months (right). The homologous prime/boost/boost regimen RTS,S/RTS,S/RTS,S was used as a reference.

Figure 12. T cell response to the N-terminus, in
25 experiments boosting with a recombinant Ad35-CS vector and priming with RTS,S or Ad5-CS, measured after two weeks (left) or after three months (right). The homologous prime/boost/boost regimen RTS,S/RTS,S/RTS,S
30 was used as a reference.

SUMMARY OF THE INVENTION

The invention relates to a kit of parts comprising a replication-defective recombinant adenovirus in a

suitable excipient, said adenovirus comprising a heterologous nucleic acid encoding a circumsporozoite (CS) antigen from a malaria-causing parasite; and an adjuvated proteinaceous antigen, preferably also from a malaria-causing parasite; wherein said recombinant adenovirus is selected from the group consisting of human adenovirus serotype 11, 24, 26, 34, 35, 48, 49 and 50. A preferred proteinaceous antigen comprises RTS,S. The preferred malaria-causing parasite is *Plasmodium falciparum*.

In another embodiment the invention also relates to the use of a replication-defective recombinant adenovirus comprising a heterologous nucleic acid encoding a CS antigen from a malaria-causing parasite, and an adjuvated proteinaceous antigen, preferably from a malaria-causing parasite such as *Plasmodium falciparum*, in the manufacture of a medicament for the treatment or prevention of malaria, wherein said recombinant adenovirus is a simian adenovirus or a human adenovirus serotype 11, 24, 26, 34, 35, 48, 49 or 50.

The invention discloses certain preferred prime-boost regimens, wherein it is preferred that the replication-defective recombinant adenovirus is used as a priming composition and the adjuvated proteinaceous antigen is used as a boosting composition.

The invention also relates to a method of vaccinating a mammal for a malaria infection comprising the steps of priming said mammal with a replication-defective recombinant adenovirus in a suitable excipient, said adenovirus comprising a heterologous nucleic acid encoding a CS antigen from a malaria-causing parasite; and boosting said mammal with an adjuvated proteinaceous antigen, preferably RTS,S.

DETAILED DESCRIPTION

The present invention relates to a kit of parts comprising a replication-defective recombinant adenovirus in a pharmaceutically acceptable excipient, said
5 adenovirus comprising a heterologous nucleic acid encoding a circumsporozoite (CS) antigen from a malaria-causing parasite; and an adjuvated proteinaceous antigen; wherein said recombinant adenovirus is selected from the group consisting of human adenovirus serotype 11, 24, 26,
10 34, 35, 48, 49 and 50. Preferably, said recombinant adenovirus is human adenovirus serotype 35. Also preferred is a kit according to the invention wherein said proteinaceous antigen comprises a CS protein, or an immunogenic fragment thereof, from a malaria-causing
15 parasite. Said proteinaceous antigen comprises preferably a hybrid protein of CS protein or an immunogenic fragment thereof fused to the surface antigen from hepatitis B virus (HbsAg), in the form of lipoprotein particles with HbsAg. In a further preferred embodiment, the
20 proteinaceous antigen comprises RTS,S. It is also preferred that said proteinaceous antigen is adjuvated with QS21 and 3D-MPL, preferably in a formulation with cholesterol-containing liposomes.

Although it is known in the art that different
25 parasites cause malaria in humans, one embodiment of the present invention is a kit of parts according to the invention, wherein said malaria-causing parasite is *Plasmodium falciparum*.

For proper immune responses it is preferred that
30 said heterologous nucleic acid is codon-optimized for increased production of the encoded protein in a mammal, preferably a human. The recombinant adenovirus may be present in a mixture with an adjuvant.

The applicability of simian adenoviruses for use in human gene therapy or vaccines is well appreciated by those of ordinary skill in the art. Besides this, other non-human adenoviruses such as canine and bovine

5 adenoviruses were found to infect human cells in vitro and are therefore also applicable for human use since their seroprevalence is low in human samples. Thus, the invention also relates to a kit of parts comprising a replication-defective recombinant simian, canine or

10 bovine adenovirus in a pharmaceutically acceptable excipient, said adenovirus comprising a heterologous nucleic acid encoding a codon-optimized circumsporozoite (CS) antigen from *Plasmodium falciparum*; and an adjuvated proteinaceous antigen comprising RTS,S, wherein it is

15 preferred that said proteinaceous antigen is adjuvated with QS21 and 3D-MPL, preferably in a formulation with cholesterol-containing liposomes.

It is disclosed by the present invention that certain prime-boost regimens provide an unexpected and

20 striking result with respect to immune responses if the different components of the kit of parts disclosed are administered in a certain order. Thus, the invention also relates to a kit of parts according to the invention, wherein said replication-defective recombinant adenovirus

25 is a priming composition and said adjuvated proteinaceous antigen is a boosting composition. The immune response triggered by a single administration (prime) of a vaccine is often not sufficiently potent and/or persistent to provide effective protection. Repeated administration

30 (boost) can significantly enhance humoral and cellular responses to vaccine antigens (e.g., see Estcourt et al. 2002).

The invention also relates to the use of a replication-defective recombinant adenovirus comprising a

heterologous nucleic acid encoding a CS antigen from a malaria-causing parasite, and an adjuvated proteinaceous antigen in the manufacture of a medicament for the treatment or prevention of malaria, wherein said

5 recombinant adenovirus is a simian, a canine, a bovine adenovirus, or a human adenovirus serotype 11, 24, 26, 34, 35, 48, 49 or 50, wherein it is preferred that said replication-defective recombinant adenovirus is used as a priming composition and said adjuvated proteinaceous

10 antigen is used as a boosting composition. According to one embodiment of the invention, it relates to a use according to the invention, wherein the proteinaceous antigen comprises a CS protein, or an immunogenic fragment thereof, from a malaria-causing parasite,

15 preferably *Plasmodium falciparum*. Said proteinaceous antigen preferably comprises a hybrid protein of CS protein or an immunogenic fragment thereof fused to the surface antigen from hepatitis B virus (HbsAg), in the form of lipoprotein particles with HbsAg. RTS,S is a

20 preferred adjuvated proteinaceous antigen, while a preferred adjuvant is QS21 and 3D-MPL, preferably in a formulation with cholesterol-containing liposomes.

For optimal expression followed by optimal immune responses in mammals, preferably humans, the heterologous

25 nucleic acid used in the present invention is codon-optimized for increased production of the encoded protein in a mammal, preferably a human.

In yet another embodiment, the present invention relates to a method of vaccinating a mammal for a malaria

30 infection comprising the steps of priming said mammal with a replication-defective recombinant adenovirus in a pharmaceutically acceptable excipient, said adenovirus comprising a heterologous nucleic acid encoding a CS antigen from a malaria-causing parasite; and boosting

said mammal with an adjuvated proteinaceous antigen comprising a hybrid protein of CS protein or an immunogenic fragment thereof fused to HbsAg, in the form of lipoprotein particles with HbsAg. The proteinaceous antigen preferably comprises RTS,S, wherein the preferred adjuvant is QS21 and 3D-MPL, preferably in a formulation with cholesterol-containing liposomes, whereas the preferred malaria-causing parasite is *Plasmodium falciparum*.

10 Preferred adenoviruses that are used to produce recombinant adenovirus and used in the methods of the present invention may be human or non-human adenoviruses such as simian-, canine- and bovine adenoviruses, since it is highly preferred to use adenoviruses that do not
15 encounter pre-existing immunity in the (human) host to which the recombinant virus is to be administered. Simian adenoviruses and certain serotypes of human adenoviruses are highly suited for this, as disclosed herein. Preferred human adenoviruses that are used for the
20 methods, uses and kit-of parts according to the invention are human adenovirus serotypes 11, 24, 26, 34, 35, 48, 49 and 50.

The invention also relates to a method of vaccinating a mammal for a malaria infection using a kit
25 of parts according to the invention. If a kit of parts according to the invention is used for vaccinating a mammal for a malaria infection using a preferred prime-boost regimen as disclosed herein, the boost is preferably followed by one or more subsequent boosts.

30

The present invention relates to the use of recombinant adenovirus as a carrier of at least one malaria antigen and used in heterologous combination with one adjuvated protein in a prime/boost regimen. It has

surprisingly been found that the combination of a viral vector and an adjuvated protein in a heterologous prime/boost regimen provides a superior immune response in primates in terms of initial T cell responses and longevity of the immune responses. In particular, it has been found that priming a mammal with a viral vector carrying a nucleic acid encoding an antigen followed by a subsequent boosting, either by single or multiple injection of adjuvated proteinaceous antigen provides superior results in terms of qualitative and/or quantitative immune responses. Preferred viral vectors are adenoviral vectors, more preferably human adenoviral vectors, and even more preferably human adenoviral vectors that encounter low levels of neutralizing activity in the mammalian host to which it is administered. Highly preferred serotypes are adenovirus 11, 24, 26, 34, 35, 48, 49 and 50.

According to one preferred embodiment, the proteinaceous antigen and the antigen encoded by the viral vector are malaria antigens, more preferably the *Plasmodium falciparum* circumsporozoite (CS) protein, or immunogenic derivatives and/or fragments thereof. As one example of this concept, the polypeptide encoded by the viral vector comprises the nucleic acid encoding the *P. falciparum* CS protein, including the N-terminal part, the central part repeat region, and the C-terminal part (with a deletion of the 14 most C-terminal amino acids: the GPI anchor sequence), while the proteinaceous antigen comprises the construct RTS,S, which lacks the N-terminal region.

The adjuvated proteinaceous antigen for use in any or all aspects of the invention may comprise the CS protein from *P. falciparum*, or an immunogenic fragment thereof, which may be in the form of a fusion protein.

For example, the antigen may comprise a hybrid protein of CS protein or an immunogenic fragment fused to the surface antigen from hepatitis B virus (HBsAg), which hybrid protein may be expressed in prokaryotic or eukaryotic host cells and may take the form of lipoprotein particles. The fusion protein may comprise for example substantially all the C-terminal portion of the CS protein, four or more tandem repeats of the immunodominant region, and the surface antigen from hepatitis B virus (HBsAg). For example the hybrid protein comprises a sequence which contains at least 160 amino acids which is substantially homologous to the C-terminal portion of the CS protein and may be devoid of the end amino acids from the C-terminal of the CS protein, for example the last 10 to 12 amino acids. The hybrid protein may be in the form of mixed lipoprotein particles, for example with HBsAg.

In particular there is provided a hybrid protein as disclosed in WO 93/10152, designated therein as "RTS*" but referred to herein as "RTS", which may be in the form of mixed lipoprotein particles with HBsAg, herein designated RTS,S. The ratio of hybrid protein:S antigen in these mixed particles is for example 1:4.

The hybrid protein designated "RTS" herein was generated using the CS protein gene sequence from *P. falciparum* NF54 (clone 3D7; Caspers et al. 1989) and comprises substantially the entire region 207 to 395 of the CS protein from *P. falciparum* NF54. The portion of the NF54 (3D7) CS protein sequence that is included in RTS is the following sequence of 189 amino acids:

DPNANPNANP NANPNANPNA NPNANPNANP NANPNANPNA NPNANPNANP
NANPNANPNA NPNANPNANP NANPNKNNQG NGQGHNMPND PNRNVDENAN
ANSAVKNNNN EEP SDKHIKE YLNKIQNSLS TEWSPCSVTC GNGIQVRIKP
GSANKPKDEL DYANDIEKKI CKMEKCSSVF NVVNSSIGL (SEQ ID NO:1).

In particular RTS is:

- 5 • A methionine residue encoded by nucleotides 1059-1061 derived from the *Sacchromyces cerevisiae* TDH3 gene sequence (nucleotides 1-1058 in this reading frame make up the TDH3 promoter itself). (Musti et al. 1983).
- 10 • Three amino acids: Met Ala Pro, derived from a nucleotide sequence (1062-1070) created by the cloning procedure used to construct the hybrid gene).
- 15 • A stretch of 189 amino acids (given above, SEQ ID NO:1) encoded by 1071-1637 representing amino acids 207 to 395 of the CS protein of *P. falciparum* strain NF54 (clone 3D7; Caspers et al. 1989).
- 20 • An amino acid (Gly) encoded by nucleotides 1638 to 1640, created by the cloning procedure used to construct the hybrid gene.
- 25 • Four amino acids, Pro Val Thr Asn, encoded by nucleotides 1641 to 1652, and representing the four carboxy terminal residues of the hepatitis B virus (adw serotype) preS2 protein (Valenzuela et al. 1979).
- 30 • A stretch of 226 amino acids, encoded by nucleotides 1653 to 2330, and specifying the S protein of hepatitis B virus (adw serotype) (Valenzuela et al. 1979).

RTS may be in the form of mixed particles, RTS,S,
30 where the ratio of RTS:S is for example 1:4.

Although the invention is by no means limited to malarial antigens, the invention will be explained in great detail using viral vectors encoding a malarial

antigen in combination with an adjuvated proteinaceous malarial antigen. Those of skill in the art will be able to modify the general teaching provided herein by using different antigenic inserts and corresponding

5 proteinaceous antigens from other pathogenic agents, including parasites, bacteria, viruses, yeasts, or even self-antigens, including, but not limited to, tumor antigens (e.g., PSA, gp100, CEA, MUC1, Her2/neu) and the like).

10

The present invention relates to a replication-defective recombinant adenoviral vector comprising a heterologous nucleic acid sequence encoding an antigen of *Plasmodium falciparum*. In a preferred embodiment said

15 viral vector is an adenovirus derived from a serotype selected from the group consisting of: Ad11, Ad24, Ad26, Ad34, Ad35, Ad48, Ad49 and Ad50. The reason for this selection of human adenoviruses is because the use of adenoviruses in general as vaccine vectors is typically

20 hampered by the fact that humans are infected regularly with wild type adenoviruses, which cause mild or inapparent diseases such as the common cold. The immune responses raised during such an infection with a parental wild-type serotype can negatively impact the efficacy of

25 the recombinant adenovirus serotype when used as a subsequent recombinant vaccine vector, such as a vaccine against malaria in which adenoviruses are applied. The spread of the different adenovirus serotypes in the human worldwide population differs from one geographic area to

30 the other. Generally, the preferred serotypes encounter a low neutralizing activity in hosts in most parts of the world, as outlined in several reports in the art.

The inventors of the present invention have now made a novel combination between a recombinant adenovirus and

a purified protein in a sequential vaccination scheme, referred to as a heterologous prime/boost, which scheme makes use of the different immune responses induced by the different components of the prime/boost vaccine.

5 Choice of the recombinant vector is influenced by those that encounter neutralizing activity in a low percentage of the human population in need of the vaccination. Surprisingly, the combination of adenovirus-vectored antigen and adjuvated protein antigen provides a
10 significant improvement in immune responses over those seen using either vaccine alone. The immune enhancement is illustrated by in vitro detection of immune responses given in vivo to rhesus macaques as disclosed herein.

In another embodiment, the recombinant replication-
15 defective adenovirus is a simian adenovirus, such as those isolated from chimpanzee. Examples that are suited include C68 (also known as Pan 9; US 6,083,716) and Pan 5, 6 and 7 (WO 03/046124).

In one particular aspect of the invention the
20 replication-defective recombinant viral vector comprises a nucleic acid sequence coding for the CS protein, or an immunogenic part or fragment thereof. Preferably, said heterologous nucleic acid sequence is codon-optimized for elevated expression in a mammal, preferably a human.
25 Codon-optimization is based on the required amino acid content, the general optimal codon usage in the mammal of interest and a number of aspects that should be avoided to ensure proper expression. Such aspects may be splice donor or -acceptor sites, stop codons, Chi-sites, poly(A)
30 stretches, GC- and AT-rich sequences, internal TATA boxes, etcetera. Methods of codon optimization for mammalian hosts are well known to the skilled person and can be found in several places in molecular biology literature.

In a preferred embodiment, the invention relates to a replication-defective recombinant adenoviral vector according to the invention, wherein the adenine plus thymine content in said heterologous nucleic acid, as compared to the cytosine plus guanine content, is less than 87%, preferably less than 80%, more preferably less than 59% and most preferably equal to approximately 45%. The invention provides, in one embodiment a replication-defective recombinant adenoviral vector, wherein the CS protein is any one of the CS proteins as disclosed in WO 2004/055187, most preferably the CS protein from *P.falciparum* or an immunogenic fragment thereof.

The production of recombinant adenoviral vectors harboring heterologous genes is well-known in the art and typically involves the use of a packaging cell line, adapter constructs and cosmids and deletion of at least a functional part of the E1 region from the adenoviral genome (see also below for packaging systems and preferred cell lines).

20

The invention also relates to kits comprising as components on the one hand a recombinant adenoviral vector that encounters low neutralizing activity in the host and on the other hand a purified protein, wherein it is preferred that the purified protein is provided in an admixture with an adjuvant. A preferred adjuvant is QS21 and 3D-MPL, preferably in a formulation with cholesterol-containing liposomes. The components are used in a heterologous prime/boost vaccine delivery strategy in which it is preferred to first administer the recombinant adenoviral vector as a priming agent and then the purified protein as a boosting agent, which boost may be repeated more than once. The components are typically held in pharmaceutically acceptable carriers.

Pharmaceutically acceptable carriers are well known in the art and used extensively in a wide range of therapeutic products. Preferably, carriers are applied that work well in vaccines. More preferred are vaccines
5 further comprising an adjuvant. Adjuvants are known in the art to further increase the immune response to an applied antigen. The invention also relates to the use of a kit according to the invention in the therapeutic, prophylactic or diagnostic treatment of malaria.

10 The present invention relates to a method of treating a mammal for a malaria infection or preventing a malaria infection in a mammal, said method comprising (in either order, or simultaneously) the steps of administering a recombinant adenovirus carrying an
15 antigen of *P.falciparum*; and administering at least one purified *P.falciparum* protein, said protein admixed with an adjuvant. Preferably the recombinant adenovirus is selected from the group consisting of Ad11, Ad24, Ad26, Ad34, Ad35, Ad48, Ad49 and Ad50, while it is also
20 preferred that the recombinant adenovirus harbors the gene encoding the CS protein, or an immunogenic fragment thereof. The preferred purified protein that is used in combination with the recombinant adenovirus is RTS,S, while a preferred adjuvant is QS21 and 3D-MPL, preferably
25 in a formulation with cholesterol-containing liposomes.

The driving force behind the development of the immune responses is cytokines, a number of identified protein messengers that serve to help the cells of the
30 immune system and steer the eventual immune response to either a Th1 or Th2 response. Thus, high levels of Th1-type cytokines tend to favor the induction of cell mediated immune responses to the given antigen, while high levels of Th2-type cytokines tend to favor the

induction of humoral immune responses to the antigen. It is important to remember that the distinction of Th1 and Th2-type immune responses is not absolute. In reality, an individual will support an immune response that is

5 described as being predominantly Th1 or predominantly Th2. However, it is often convenient to consider the families of cytokines in terms of that described in murine CD4+ T cell clones by Mosmann and Coffman (1989). Traditionally, Th1-type responses are associated with the

10 production of the INF- γ and IL-2 cytokines by T-lymphocytes. Other cytokines often directly associated with the induction of Th1-type immune responses are not produced by T-cells, such as IL-12. In contrast, Th2-type responses are associated with the secretion of IL-4, IL-

15 5, IL-6, IL-10 and tumour necrosis factor- (TNF-ss).

Suitable adjuvants for use in the invention include an aluminium salt such as aluminium hydroxide gel (alum) or aluminium phosphate, but may also be a salt of calcium, iron or zinc, or may be an insoluble suspension

20 of acylated tyrosine, or acylated sugars, cationically or anionically derivatised polysaccharides, polyphosphazenes, or montanide liposomes.

In the formulation of vaccines for use in the invention, in the context of the adenovirus vector, an

25 adjuvant may or may not be administered. In the case of the protein component of the combination, the adjuvant composition may be selected to induce a preferential Th1 response. Moreover, other responses, including other humoral responses, may also be induced.

30 Certain vaccine adjuvants are particularly suited to the stimulation of either Th1 or Th2-type cytokine responses. Traditionally, the best indicators of the Th1: Th2 balance of the immune response after a vaccination or infection includes direct measurement of the production

of Th1 or Th2 cytokines by T lymphocytes in vitro after restimulation with antigen, and/or the measurement of the IgG1: IgG2a ratio of antigen specific antibody responses. Thus, a Th1-type adjuvant is one, which stimulates
5 isolated T-cell populations to produce high levels of Th1-type cytokines when re-stimulated with antigen in vitro, and induces antigen specific immunoglobulin responses associated with Th1-type isotype. For example, Th1-type immunostimulants which may be formulated to
10 produce adjuvants suitable for use in the present invention may include Monophosphoryl lipid A, in particular 3-de-O-acylated monophosphoryl lipid A (3D-MPL). 3D-MPL is a well-known adjuvant manufactured by Ribi Immunochem, Montana. Chemically it is often supplied
15 as a mixture of 3-de-O-acylated monophosphoryl lipid A with either 4,5, or 6 acylated chains. It can be purified and prepared by the methods taught in GB 2122204B, which reference also discloses the preparation of diphosphoryl lipid A, and 3- O-deacylated variants thereof. Other
20 purified and synthetic lipopolysaccharides have been described (US Pat. 6,005,099, EP 0729473 B1, EP 0549074 B1). In one embodiment, 3D-MPL is in the form of a particulate formulation having a small particle size less than 0.2 μm in diameter, and its method of manufacture is
25 disclosed in EP 0689454.

Saponins are another example of Th1 immunostimulants that may be used with the invention. Saponins are well known adjuvants. For example, Quil A (derived from the bark of the South American tree *Quillaja Saponaria*
30 *Molina*), and fractions thereof, are described in US Pat. 5,057,540, and EP 0362279 B1. The haemolytic saponins QS21 and QS17 (HPLC purified fractions of Quil A) have been described as potent systemic adjuvants, and the method of their production is disclosed in US Pat.

5,057,540 and EP 0362279 B1. Also described in these references is the use of QS7 (a non-haemolytic fraction of Quil-A), which acts as a potent adjuvant for systemic vaccines. Combinations of QS21 and polysorbate or cyclodextrin are also known (WO 99/10008). Particulate adjuvant systems comprising fractions of QuilA, such as QS21 and QS7 are described in WO 96/33739 and WO 96/11711.

Yet another example of an immunostimulant is an immunostimulatory oligonucleotide containing unmethylated CpG dinucleotides ("CpG"). CpG is an abbreviation for cytosine-guanosine dinucleotide motifs present in DNA. CpG is known in the art as being an adjuvant when administered by both systemic and mucosal routes (WO 96/02555, EP 0468520). Historically, it was observed that the DNA fraction of bacillus Calmette-Guerin (BCG) could exert an anti-tumor effect. In further studies, synthetic oligonucleotides derived from BCG gene sequences were shown to be capable of inducing immunostimulatory effects (both in vitro and in vivo). The authors of these studies concluded that certain palindromic sequences, including a central CG motif, carried this activity. Detailed analysis has shown that the CG motif has to be in a certain sequence context, and that such sequences are common in bacterial DNA but are rare in vertebrate DNA. The immunostimulatory sequence is often: Purine, Purine, C, G, pyrimidine, pyrimidine; wherein the CG motif is not methylated, but other unmethylated CpG sequences are known to be immunostimulatory and may be used in the present invention.

In certain combinations of the six nucleotides, a palindromic sequence may be present. Several of these motifs, either as repeats of one motif or a combination of different motifs, can be present in the same

oligonucleotide. The presence of one or more of these immunostimulatory sequences containing oligonucleotides can activate various immune subsets, including natural killer cells (which produce interferon γ and have
5 cytolytic activity) and macrophages. Other unmethylated CpG containing sequences not having this consensus sequence have also now been shown to be immunomodulatory. When formulated into vaccines, CpG is generally administered in free solution together with free antigen
10 (WO 96/02555, 68) or covalently conjugated to an antigen (WO 98/16247), or formulated with a carrier such as aluminium hydroxide (Hepatitis surface antigen).

Such immunostimulants as described above may be formulated together with carriers, such as, for example,
15 liposomes, oil in water emulsions, and or metallic salts, including aluminium salts (such as aluminium hydroxide). For example, 3D-MPL may be formulated with aluminium hydroxide (EP 0689454) or oil in water emulsions (WO 95/17210); QS21 may be advantageously formulated with
20 cholesterol containing liposomes (WO 96/33739), oil in water emulsions (WO 95/17210) or alum (WO 98/15287); CpG may be formulated with alum or with other cationic carriers.

Combinations of immunostimulants may also be used,
25 such as a combination of a monophosphoryl lipid A and a saponin derivative (WO 94/00153; WO 95/17210; WO 96/33739; WO 98/56414; WO 98/05355; WO 99/12565; WO 99/11241) or a combination of QS21 and 3D-MPL as disclosed in WO 94/00153. Alternatively, a combination of
30 CpG plus a saponin such as QS21 may also be used in the present invention. Thus, suitable adjuvant systems include, for example, a combination of monophosphoryl lipid A, such as 3D-MPL, together with an aluminium salt. Another embodiment combines a monophosphoryl lipid A and

a saponin derivative, such as the combination of QS21 and 3D-MPL as disclosed in WO 94/00153, or a less reactogenic composition where the QS21 is quenched in cholesterol containing liposomes (DQ) as disclosed in WO 96/33739.

5 Yet another adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil in water emulsion is described in WO 95/17210. In another embodiment, CpG oligonucleotides are used alone or together with an aluminium salt.

10 A suitable adjuvant for use in the present invention is a preferential Th1 stimulating adjuvant, for example an adjuvant comprising a saponin such as QS21 or a monophosphoryl lipid A derivative such as 3D-MPL, or an adjuvant comprising both of these optionally together
15 with cholesterol-containing liposomes. A combination of QS21 and 3D-MPL in a formulation with cholesterol-containing liposomes is described for example in WO 96/33739

The advantages of the present invention are multi-
20 fold. Recombinant viruses, such as recombinant adenoviruses, can be produced to very high titers using cells that are considered safe, and that can grow in suspension to very high volumes, using medium that does not contain any animal- or human derived components.

25 Also, it is known that recombinant adenoviruses elicit a dramatic immune response against the protein encoded by the heterologous nucleic acid sequence in the adenoviral genome. The present invention combines these features in a vector harboring the circumsporozoite gene of
30 *P.falciparum* with the use of adjuvated protein to boost responses. Moreover, the gene has been codon-optimized to give an expression level that is suitable for giving a proper immune response in humans. The present invention provides a vaccine against malaria infections, making use

of adenoviruses that do not encounter high titers of neutralizing antibodies. Highly preferred adenoviruses for this purpose are serotype 11 and 35 (Ad11 and Ad35, see WO 00/70071 and WO 02/40665).

5 The nucleic acid content between the malaria-causing pathogen, such as *P.falciparum* and the host of interest, such as *Homo sapiens* is very different. The invention provides codon-optimised nucleic acids providing higher expression levels in mammals, such as humans.

10 The use of different entities for prime/boost regimens as disclosed herein provides a vaccine method that provides for proper immune responses of both cellular and humoral arms of the immune system. It involves CD8+ T cells, CD4+ T cells and antibodies.

15 Neither of these vaccines alone establishes a sustainable immune response that invokes optimal levels of antigen-specific CD8+ T cells, CD4+ T cells and antibodies. Moreover, the order in which the different components are administered may alter these immune responses and may

20 give rise to different periods of possible protection against future infections. The methods and kits of the present invention enable one to elicit an immune response that deals with all the different stages of the

25 parasite's life cycle in humans, from free circulating sporozoites and merozoites to infected hepatocytes and RBC's. Moreover, it provides a sustained protection against malaria infections over a prolonged period of time.

30 In a preferred embodiment, the invention relates to the use of recombinant adenoviruses that are replication defective through removal of at least part of the E1 region in the adenoviral genome, since the E1 region is required for replication-, transcription-, translation-

and packaging processes of newly made adenoviruses. E1 deleted vectors are generally produced on cell lines that complement for the deleted E1 functions. Such cell lines and the use thereof for the production of recombinant viruses have been described extensively and are well known in the art. Preferably, PER.C6[®] cells, as represented by the cells deposited under ECACC no. 96022940 at the European Collection of Animal Cell Cultures (ECACC) at the Centre for Applied Microbiology and Research (CAMR, UK), or derivatives thereof are being used to prevent the production of replication competent adenoviruses (rca). In another preferred embodiment, cells are being applied that support the growth of recombinant adenoviruses other than those derived for adenovirus serotype 5 (Ad5). Reference is made to publications WO 97/00326, WO 01/05945, WO 01/07571, WO 00/70071, WO 02/40665 and WO 99/55132, for methods and means to obtain rca-free adenoviral stocks for Ad5 as well as for other adenovirus serotypes, such as recombinant replication-defective Ad35 which may be produced on HER cells immortalized with E1 from Ad35, or on PER.C6[®] cells that further comprises E1 genes from Ad35 to provide proper complementation of B-type adenoviruses.

It must be noted here that in the published documents WO 00/03029, WO 02/24730, WO 00/70071 and WO 02/40665, Ad50 was mistakenly named Ad51. The Ad51 serotype that was referred to in the mentioned publications is the same as serotype Ad50 in a publication by De Jong et al. (1999), wherein it was denoted as a B-group adenovirus. For the sake of clarity, Ad50 as used herein, is the B-group Ad50 serotype as mentioned by De Jong et al. (1999).

The vaccines of the present invention are typically used in prime/boost settings, for example Ad/protein;

protein/Ad; protein/Ad/Ad; Ad/protein/Ad; Ad/Ad/protein,
Ad/protein/protein/protein, Ad/protein/viral
vector/protein, etc, etc. It may be envisioned that a
combination with yet another kind of vaccine (such as
5 naked DNA or a recombinant viral vector different from
adenovirus) may be applied in combination with the
prime/boost agents of the present invention. Additional
malarial antigens or (poly)peptides may also be used.

10 A sequence is 'derived' as used herein if a nucleic
acid can be obtained through direct cloning from wild-
type sequences obtained from wild-type viruses, while
they can for instance also be obtained through PCR by
using different pieces of DNA as a template. This means
15 also that such sequences may be in the wild-type form as
well as in altered form. Another option for reaching the
same result is through combining synthetic DNA. It is to
be understood that 'derived' does not exclusively mean a
direct cloning of the wild type DNA. A person skilled in
20 the art will also be aware of the possibilities of
molecular biology to obtain mutant forms of a certain
piece of nucleic acid. The terms 'functional part,
derivative and/or analogue thereof' are to be understood
as equivalents of the nucleic acid sequence they are
25 related to. A person skilled in the art will appreciate
the fact that certain deletions, swaps, (point)
mutations, additions, etcetera may still result in a
nucleic acid sequence that has a similar function as the
original nucleic acid sequence, and should produce a
30 similar or even identical polypeptide once translated. It
is therefore to be understood that such alterations that
do not significantly alter the functionality of the
nucleic acid sequences are within the scope of the
present invention. If a certain adenoviral vector is

derived from a certain adenoviral serotype of choice, it is also to be understood that the final product may be obtained through indirect ways, such as direct cloning and synthesizing certain pieces of genomic DNA, using methodology known in the art. Certain deletions, mutations and other alterations of the genomic content that do not alter the specific aspects of the invention are still considered to be part of the invention. Examples of such alterations are for instance deletions in the viral backbone to enable the cloning of larger pieces of heterologous nucleic acids. Examples of such mutations are for instance E3 deletions or deletions and/or alterations in the regions coding for the E2 and/or E4 proteins of adenovirus. Such changes applied to the adenoviral backbone are known in the art and often applied, since space is a limiting factor for adenovirus to be packaged; this is a major reason to delete certain parts of the adenoviral genome. Other reasons for altering the E2, E3 and/or E4 regions of the genome may be related to stability or integrity of the adenoviral vector, as for instance described in WO 03/104467 and WO 2004/001032). These applications relate amongst others to the use of an E4orf6 gene from a serotype from one subgroup in the backbone of an adenovirus from another subgroup, to ensure compatibility between the E4orf6 activity and the E1B-55K activity during replication and packaging in a packaging cell line. They further relate to the use of a proper functioning pIX promoter for obtaining higher pIX expression levels and a more stable recombinant adenoviral vector.

'Replication defective' as used herein means that the viral vectors do not replicate in non-complementing cells. In complementing cells, the functions required for replication, and thus production of the viral vector, are

provided by the complementing cell. The replication defective viral vectors of the present invention do not harbor all elements enabling replication in any host cell other than a complementing cell.

5 'Heterologous' as used herein in conjunction with nucleic acids means that the nucleic acid sequence derives from a different original source than the wild type versions of the viral vectors in which the heterologous nucleic acid is cloned. For instance in the
10 case of adenoviruses, the heterologous nucleic acid that is cloned in the replication defective adenoviral vector, is not an adenoviral nucleic acid sequence, but comes from some other pathogenic agent of interest.

 'Heterologous' as used herein in conjunction with
15 prime-boost vaccine strategies means that two or more separate components, exemplified by one recombinant non-replicative adenovirus vector and one adjuvated protein used in deliberate combination, rather than one component being administered several times, as is usual in the
20 industry thus far.

 'Antigen' as used herein means any antigen derived from a source that elicits an immune response in a host to which the determinant is delivered (administered). The antigen may be from an external source, e.g. a pathogen,
25 a parasite, or even be a self-antigen. Examples of antigens of *Plasmodium* that can be delivered by using the replication defective recombinant viruses of the present invention are the circumsporozoite protein (CS), the SE36 polypeptide, the merozoite surface protein-1 19 kDa C-
30 terminal polypeptide (MSP-1p19), MSP-1, MSP-1p42, Apical Merozoite Antigen-1 (AMA-1), Liver Stage Antigen 1 (LSA-1) or Liver Stage Antigen-3 (LSA-3), or a fragment of any of the aforementioned. In a preferred aspect the

invention relates to the circumsporozoite (CS) protein from *P.falciparum*.

'Codon-optimized' as used herein means that the nucleic acid content of a sequence has been altered to support sufficiently high expression levels of the protein of interest in a host of interest to which the gene encoding said protein is delivered. Sufficiently high expression levels in this context means that the protein levels should be high enough to elicit an immune response in the host in order to protect against infection or against disease. It is known in the art that some vaccines give an immune response in humans, through which approximately 60% of the vaccinated individuals is protected against illnesses induced by subsequent challenges with the pathogen (e.g., sporozoites). Therefore the expression levels are considered to be sufficient if 60% or more of the treated individuals is protected against subsequent infections. It is believed that with the combinations of adenoviral aspects that can be applied and the choice of antigen as disclosed herein, such percentages may be reached. Preferably, 85% of the individuals are protected, while it is most preferred to have protection to a subsequent challenge in more than 90% of the vaccinated hosts. The nucleic acids disclosed in the present invention are codon-optimized for expression in humans. According to Narum et al. (2001), the content of adenine plus thymine (A+T) in DNA of *Homo sapiens* is approximately 59%, as compared to the percentage cytosine plus guanine (C+G). The adenine plus thymine content in *P.falciparum* overall is approximately 80%. The adenine plus thymine content in the CS gene of *P.falciparum* is approximately 87%. To obtain sufficient protection it is believed to be necessary to improve production levels in the host. One way to achieve this is

to adjust codon usage to maintain the same ultimate amino acid sequence, but use codon sequences more typical of mammalian expression. For this, the replication-defective recombinant viral vectors according to the invention have
5 an adenine plus thymine content in the heterologous nucleic acids of the present invention of less than 87%, preferably less than 80%, and more preferably less than or equal to approximately 59%. Based on codon-usage in human and the amino acid content of the CS genes of
10 *P.falciparum* and *yoelii*, the percentages of the codon-optimized genes were even lower, reaching approximately 45% for the amino acid content as disclosed by the present invention. Therefore, as far as the CS genes are concerned it is preferred to have an adenine plus thymine
15 content of approximately 45%. It is to be understood, that if another species than humans is to be treated, which may have a different adenine plus thymine concentration (less or more than 59%), and/or a different codon usage, that the genes encoding the CS proteins of
20 the present invention may be adjusted to fit the required content and give rise to suitable expression levels for that particular host. Of course, it cannot be excluded either, that slight changes in content may result in slight expression level changes in different geographical
25 areas around the world. It is also to be understood that slight changes in the number of repeats included in the amino acid sequence of the proteins, that percentages may differ accordingly. Other antigens of interest may be similarly modified. All these adjusted contents are part
30 of the present invention.

The protein designated RTS,S is a fusion protein consisting of the C-terminal half of the *P. falciparum* CS protein (17 of the central 41 NANP-repeats plus most of

the C-terminal portion) expressed as a fusion protein with the Hepatitis B Surface antigen.

One of the distinct advantages offered by the replication-incompetent adenoviral vectors is the minor pathogenicity of the parental viruses and the documented lack of significant disease caused by these vectors in any individual, including those who are immunosuppressed. Work in the mouse model of malaria, *P. yoelii*, indicated that recombinant adenovirus constructs expressing the CS protein not only engender outstanding cellular immune responses, they provide excellent protection against infection. Therefore, in an effort to improve the intensity of the T cell response and the longevity of the overall immune response to CS, the inventors of the present invention decided to combine an adenoviral approach with the recombinant protein approach in a novel heterologous prime-boost strategy.

Unfortunately, the mouse is not the ideal model for predicting responses in humans. This is particularly true for Adenovirus 35 (Ad35). The standard replication-incompetent vector is Adenovirus 5 (Ad5), which has demonstrated some problems with optimizing its vector capabilities due to the widespread endemicity of this virus and the fact that a substantial proportion of most global human populations have pre-existing immunity to the parental virus. Ad35 has the potential to demonstrate enhanced utility as a vaccine vector. The availability of both Ad5 and Ad35 CSP-bearing constructs allowed evaluation of two sequential heterologous adenoviral immunizations with differing constructs specifically for the question of CS immunity.

Dendritic cells (DC) are the most potent antigen-presenting cells in the body, and the fact that both Ad5 and Ad35 target to human and rhesus DC is one of the

aspects of their biology that makes them such excellent vaccine vectors. However, only Ad5 efficiently infects murine DC; Ad35 only reliably infects primate DC. Thus, although basic potency questions about Ad35 constructs can be answered in small animal models, actual immunogenicity questions involving Ad35 can only be asked in non-human primates.

The inventors decided to examine the prime-boost combinations of RTS,S with adenoviral vectors containing the CS gene to determine if the anti-malarial cellular and/or humoral responses would be an improvement upon the responses seen to RTS,S alone. In addition, a regimen for two doses of adenovirus vaccine alone was optimized.

15

EXAMPLE

Heterologous prime/boost vaccination using recombinant adenoviral vectors and purified adjuvated protein in rhesus monkeys.

The objectives of the experiment were to evaluate RTS,S followed by Ad35, and Ad35 followed by RTS,S, in a direct comparison with a standard three-dose RTS,S immunization regimen and a standard two-dose Ad35 regimen. A secondary objective was to optimize the two-dose adenovirus regimen. The serologic and cellular immune responses during and after several different regimens of these constructs in combination were studied.

The rhesus monkey (*Macaca mulatta*) makes an excellent model for the human immune response because of its much closer phylogenetic relationship. MHC Class II alleles are particularly well conserved; the generation of some shared alleles is estimated at 25 million years ago, predating the speciation of human and rhesus. Thus,

there is similar epitope usage in presentation of antigen to Th cells, which greatly enhances the predictive value of the model. More importantly, the rhesus monkey model has in the past been proven to be highly predictive of
5 the human immunogenicity responses both for malaria antigens and for HIV, another human disease for which the development of a vaccine has been hindered by the complexity of the immune response.

Preliminary experiments have already been performed
10 in mice with adenoviral-CS constructs of the mouse malaria *P. yoelii* that demonstrated excellent immunogenicity and protective efficacy. However, the long history of unsuccessful attempts to directly extrapolate from the mouse malaria model to humans in the quest for
15 development of vaccines for falciparum malaria mandates an intermediate step in a non-human primate model. The rhesus macaque represents the best choice of species because of the extensive database of prior information on these vaccines in this species, because of the
20 phylogenetic proximity to humans, because their size permits blood samples of sufficient volume to ensure adequate assessment of immune responses, and because reagents and assays exist that are already optimized for this species and thus do not require ancillary protocols
25 and many years to develop. Additionally, the adenovirus 35 constructs can only be appropriately tested in non-human primates, because of the inability of this virus to efficiently invade the dendritic cells of other mammals.

30 The constructs and the production of the recombinant, replication-defective adenoviruses harboring the *P.falciparum* CS encoding gene (Ad5CS and Ad35CS) used in this study have been described in great detail in the examples of WO 2004/055187 (clone 02-659; see fig. 2

therein). Briefly, these adenovectors comprise a heterologous gene encoding for the CS protein with an amino acid sequence that is similar to the CS protein of the NF54 strain, 3D7 clone, having amongst others, an N-terminal signal sequence, 27 NANP repeats, a cluster of 3 NVDP repeats and one separate NVDP repeat, the universal epitope (Lockyer et al. 1989; Zevering et al. 1994; Nardin et al. 2001), and a deletion of the last 14 amino acids (at the C-terminus). The difference with the protein of RTS,S is that RTS,S lacks the N-terminal signal sequence, and a large portion of the repeat region, as well as most of the C-terminally located GPI anchor signal sequence which is also absent in the adenoviral constructs.

15

The experiment was a randomized, blinded safety and immunogenicity study of various combinations and timing strategies for optimization of prime-boost strategies of RTS,S with Ad5 and Ad35 CS-bearing constructs (Ad5CS and Ad35CS) and for optimization of Ad5CS and Ad35CS alone. The previous best regimen against which the new strategies were compared were three intramuscular doses of 50 µg of RTS,S with adjuvant given at 0, 1, and 3 months. This was Group 1, the Positive Control group. All groups are outlined in Table 1A. In all cases the adjuvant was made up of 50 µg of 3D-MPL, 50 µg QS21, in a formulation with cholesterol-containing liposomes as described in WO 96/33739.

Group 2 received two doses of RTS,S/Adjuvant at 0 and 1 month followed by one dose of Ad35CS at 3 months. Group 3 received one dose of Ad35CS at month 0 followed by two doses of RTS,S/Adjuvant at 1 and 3 months.

Groups 4, 5, and 6 only received adenoviral constructs. Prior experience with two doses of adenovirus 5 constructs in different diseases has indicated that optimal serologic and cellular immune responses are obtained when the interval between immunizations is at least 6 months. Because of the necessity to evaluate Ad35 constructs in humans or non-human primates, the optimal time between doses for this vector was not yet established. Thus, Group 4 received two doses of Ad35CS on a 0, 3 month schedule (for a direct control to the protein groups), and Group 5 got two doses on a 0, 6 month schedule. In order to evaluate the question of whether two doses of the same adenovirus construct were inferior to alternation of constructs for the CS protein, Group 5 was compared with Group 6, which received Ad5CS followed by Ad35CS on the 0, 6 month schedule. Finally, control Group 7 got two doses of plain (no malaria gene insert) Ad35 at 0 and 3 months to serve as an immunization control group for immunogenicity assessments.

Injection sites were clipped and clearly marked to facilitate observation of vaccine reactogenicity. Additionally, the animals were sedated and the injection site was directly examined for signs of induration, swelling, heat, redness, or other abnormality at 24, 48, and 72 h and at 7 and 14 days post injection. Although signs of systemic toxicity were not expected, the animals were also sedated and examined at these time points for lymphadenopathy, cellulitis, abscessation, arthritis, anorexia, and weight loss, and their hematologic and clinical chemistry values were monitored for alterations. Blood was drawn at the time of injection and at 24, 48, 72 h and 7 and 14 days after each injection for complete

blood count (CBC) and for a panel of clinical chemistry assays that included (but not necessarily limited to) determinations of BUN, creatinine, AST, ALT, GGT, and CK. Fecal samples to confirm the absence of non-replicative vector shedding were collected and saved at -70°C on each of Days 0-10 for each adenovirus injection, for subsequent adenovirus testing.

1-3 mls of serum was collected at the time of and 1, 2, and 4 weeks after every injection, and at least once monthly thereafter to determine the nature and magnitude of the antibody response to CS R32 (the repeat region of the CS protein used to develop the standardized ELISA assay to the CS protein, see below) by ELISA. Serum samples were stored at -70°C until use, and the samples were batch processed near the end of the experiment to minimize intra-assay variability. Volumes of serum collected were adequate so that for each adenovirus injection, 0.5-1.0 ml of serum from Day 0, 1, 7 and 14, and at least every 4 weeks thereafter can be used for anti-adenovirus antibody titer determination. Large volumes (20-40 ml) of EDTA- or heparin-anti-coagulated blood was collected for cell harvests prior to the first immunization, 4 weeks after the second immunization (if volume demands permit), 4 weeks after the third immunization, and 6 months after the third immunization. Peripheral blood mononuclear cells (PBMC) were concentrated from these samples using standard methods of density centrifugation separation. Although cell yields can be highly variable from one individual animal to another, in general the larger the volume of the sample, the greater the number of recovered cells. Because it is impossible to predict the exact cell recovery, it is preferred to take a larger sample where possible so that

enough cells were obtained to repeat assays for purposes of statistical validity. Cells were frozen to permit batch processing at a later time point and thereby improve quality control. Cells were frozen in autologous serum with 10% DMSO at a controlled temperature reduction rate and stored in vapor-phase liquid nitrogen for at least a week before use.

From the larger animals whose CBC data indicated it would be well tolerated, an additional sample for cell harvest was collected after the prime, but before the boost. Since there were 14 monkeys (two groups) that received two doses of RTS,S/Adjuant and 14 monkeys that received a single dose of Ad35CS prior to the 8th week, it was expected to sample at least half and thereby maintain statistical significance. Cell harvests would occur no sooner than 4 weeks after an injection. Since the groups getting only adenovirus constructs received only two injections, and thus have a less demanding bleeding schedule than the monkeys receiving three injections, a cell harvest intermediate between the two injections was expected to pose no hardship.

Analyses of cellular immune responses included short-term ELISPOT assays for quantitation of antigen-specific IFN- γ producing cells. Flow cytometric analysis of antigen-stimulated cells cannot only confirm data gathered in ELISPOT analyses, but provides additional information about the phenotype of the antigen-specific cells that are responding. Thus, determination of the antigen-specific CD8+ IFN- γ secreting subset by intracellular staining and flow cytometry is also investigated.

Additional assays that are performed include bulk ELISpot analyses for additional cytokines, intracellular staining for T cell subset enumeration of additional

cytokines, other flow-cytometric-based assays for quantitation of antigen-specific T cell subset cytokine production, and quantitative RT-PCR for correlation with the other methods.

5

Monkeys were divided into groups evenly matched for age, sex, weight, and geographical origin, and groups were then randomized. All clinical assessments and safety endpoint determinations were determined without knowledge of the group assignment of the monkeys. Similarly, all immunological assays were performed without prior knowledge of the groups to which the individual samples belong. The exception to this blinding policy were the animals receiving immunizations on a 0 and 6 month schedule as opposed to 0, 1, and 3; however, blinding was maintained as to the specific injection being given.

A group size of seven animals per test group (and four in the control group) is ideal to minimize group size but to still accurately detect differences between groups, based on prior data from similar, but only distantly related, experiments.

The geometric means of results of ELISA assays were compared parametrically using standard analyses such as Student's t-test, assuming equal variance and two tails, and ANOVA. Results of ELISPOT assays, expressed in spots per 200,000 cells, were treated similarly and were also examined using non-parametric analyses such as the Kruskal-Wallis test. Where intergroup comparisons are required, the Student's t-test, on raw or log-transformed data, is used to determine differences between any pair of groups.

Prior to injection, the hair was clipped and the skin cleaned with 70% rubbing alcohol, and a 2.5-3 cm

circle drawn on the skin in indelible ink to facilitate locating the injection site for subsequent palpation and reactogenicity assessment. Injections of RTS,S were mixed with the adjuvant immediately prior to entering the monkey corridor. The final injection volume was 0.5 ml and delivered through a 25-29 gauge needle into the anterior thigh musculature. Adenovirus constructs were prepared as described (WO 2004/055187) in buffered saline and also administered in the same intramuscular location in a final volume of 0.5 ml.

The primary biosample was blood, whether for serum or cells. A bleeding schedule is outlined in Table 1B. The animals' hematologic status was monitored; indicating the capacity of an individual to maintain repeated biosampling or signifying that the planned biosampling schedule be reduced. Every time blood was taken, a complete blood count (CBC) was performed with a Coulter automated blood cell counter (requiring <50 µl uncoagulated blood). The manufacturer's recommended GLP-like guidelines for maintenance and upkeep were performed. Hematocrit, hemoglobin, mean corpuscular volume (MCV), red blood cell (RBC) count, and reticulocyte percentage were followed closely to assure that the animals did not become anemic.

Venous blood was collected from the femoral, saphenous, or cephalic veins using 20-24 gauge needles and either syringes or vacuum tubes. In general, the saphenous or cephalic veins were preferred for blood draws of less than 10 ml, and the femoral veins were preferred to avoid hemolysis and shorten total venipuncture time when volumes of greater than 10 ml were removed.

Peripheral Blood Mononuclear cells (PBMC's) were harvested from the animals before immunization, two weeks after the final immunization, and three months after the final immunization. In this protocol, PBMC's are

5 separated by standard methods of density centrifugation, and cryopreserved in 45% autologous serum (45% saline and 10% DMSO). Briefly, whole blood was layered on Lymphoprep® (Axis-Shield, Oslo, Norway) ficoll-hypaque cell separation medium and centrifuged at 650g for 20 min. The

10 cell layer was removed and washed in two washes of dPBS (BioWhittaker, Walkersville, MD) at 400g for 15 min. Viable cells were counted using a Coulter ACT*10 hemocytometer. Pellets were resuspended to 1×10^7 /ml in 50% dPBS, 50% saline. DMSO was added dropwise to a final 10%

15 volume. Cells were frozen in 0.55 ml aliquots of exactly 5 million cells each by placing in a controlled temperature reduction isopropanol bath in the -70°C freezer overnight, and stored in liquid nitrogen vapor phase until use.

20 After the last vaccination, interferon gamma (IFN- γ) secreting T cells in blood samples from the different monkeys were identified with the enzyme-linked immunospot (ELISpot) assay after stimulation with whole antigens and C- and N-terminal specific peptide pools (as described in

25 detail below). Results are plotted in figure 1 (2 weeks after the last vaccination) and figure 2 (3 months after the last vaccination), and expressed in table 2 and 4, respectively, as median spot forming units per million cells (SFU); statistical comparison was done using

30 analysis of variance (ANOVA) on log-transformed data. All groups were compared. In case statistical significance was determined a post-hoc analysis can be done for a group-by-group comparison (results not shown).

To compare ELISpot results between different treatment strategies, ratios of geo mean titers were calculated for strategies with Ad35 as prime treatment. In these ratios the geo mean titer obtained with treatment with RTS,S alone (at 0, 2, 3 months) was taken as reference treatment (figure 5 and 6, and table 10). Similarly, ratios were also calculated for strategies with Ad35 as boost treatment (figure 7 and 8, and table 11).

Similar analyses were done for the results of N terminus-specific stimulation T cell ELISpots. Results are plotted in figures 9 and 10, and in tables 12 and 14, respectively. Finally, ratios were calculated and presented in figure 11 (Ad35 priming strategies) and figure 12 (Ad35 boosting strategies), and tables 16 and 17, respectively.

ELISpots were performed on thawed cryopreserved PBMC's in PVDF-bottomed MultiScreen-IP ELISpot plates (Millipore, Bedford, MA) using standard methodology. Sterile technique was strictly adhered to until the cells were removed on Day 2 for final spot development.

Media used: Complete media (cRPMI) was freshly prepared from RPMI-1640 (BioWhittaker, Walkersville, MD) with the addition of 1:100 penicillin/streptomycin, 1:100 L-glutamine, 1:200 NaHCO₃ (Sigma, St. Louis, MO), 1:100 Non-Essential Amino Acids, 1:100 Pyruvate, and 1:300 2-ME (Gibco). Fetal Calf Serum (FCS, HyClone, Logan, UT), of a lot previously characterized by nonspecific proliferation assay to support good monkey cell growth yet provide little stimulatory background, was added at 10% final volume for cRPMI-10, 20% for cRPMI-20, etc. Media-Plus (M+) was additionally supplemented with anti-monkey CD28

and anti-monkey CD49D antibodies at 1:500 (BD Pharmingen, San Jose, CA).

The following stimulants were prepared fresh at
5 twice the intended final concentration in M+ without added serum:

Con A: Concanavalin A (Sigma) at 2.5 µg/ml (final 1.25 µg/ml) as a positive control for all vials.

CS-C: a pool of 15-mer polypeptides, overlapping by 11
10 amino acids, covering the C-terminal portion of the PfCS molecule (supplied by GSK, Rixensart, Belgium) at 2.5 µg/ml of each peptide (1.35 µg/ml final).

CS-N: a similar pool of 15mer peptides, overlapping by 11, covering the N-terminus of the PfCS molecule.

RTS,S: purified whole protein complex RTS,S antigen
15 suitable for cell culture (GSK) at 2 µg/ml (1 µg/ml final).

HEF: purified Hepatitis B surface antigen (HbS) whole protein (the "S" component of RTS,S), also suitable for
20 cell culture (GSK) at 23.2 µg/ml (11.6 µg/ml final).

HbS-P: a pool of HbS 15mer peptides (GSK) at 2.5 µg/ml each peptide (1.25 µg/ml final).

The negative control was M+ without further supplementation.

25

Plates were prepared as follows. Plates were coated with 50 µl/well of a 1:100 dilution in sterile dPBS of the primary mmonoclonal anti-monkey IFN-γ antibody (UcyTech #21-43-09, Utrecht, the Netherlands), and
30 incubated in a plastic bag at 4°C for 5-6 h. 1 h prior to use, the coating antibody was removed and the plate were blocked with cRPMI-10 in a 37°C, 5% CO₂ humidity-controlled cell culture incubator. Immediately prior to use, the blocking media was removed.

Thawing cryopreserved PBMC: Frozen vials were swirled in warm tap water (37-40°C just until barely thawed, and the 0.55 ml contents immediately transferred to 8 ml RPMI-20. Cells were washed at 350g for 13 min,
5 and the pellet carefully resuspended in 2.0 ml cRPMI-20. A sterile 40 µl aliquot was then removed to confirm viable cell numbers, and the volume adjusted as necessary to yield a single cell suspension of 2×10^6 cells/ml.

Pre-stimulation: equal volumes of cell suspension in
10 cRPMI-20 and stimulants in M+ were mixed in polypropylene cell culture tubes to give the final desired concentration of all reagents. Cells were then stored in the incubator for at least 5 h, with loose caps and in a tipped position to facilitate gas exchange.

15 Final stimulation: After 5-6 h of incubation, the cells were spun at 400g for 10 min and the supernatants discarded. Cells were then immediately again resuspended in half cRPMI-20 and half stimulant. They were returned to the incubator for 10-20 min to allow pH stabilization.
20 Then, cells were briefly mixed and 200 µl (200,000 cells) carefully pipetted into the appropriate wells on the blocked and emptied plates. Care was taken at all steps to ensure that the wells did not dry out. The plates were then incubated undisturbed overnight (> 16 h).

25 Spot development: A 1:100 dilution of secondary polyclonal anti-monkey-IFN-γ antibody (UCyTech) was made in dPBS with 2% FCS. Cells and media were flicked out of the plate; the wells were washed 8 times with dPBS-0.5% Tween 20 (Sigma), and loaded with 50 µl of the diluted
30 secondary antibody. Plates were incubated on a rocking panel for 3 h at room temperature in a plastic bag. Plates were washed again 8 times with dPBS-0.5% Tween 20 and loaded with 50 µl/well of a 1:1000 dilution of Streptavidin-Alkaline Phosphatase conjugate (Southern

Biotech #7100-04, Birmingham, AL). Plates were then incubated for an additional 2 h at room temperature in a plastic bag on the rocker panel. Finally, the plates were washed 8 times as before, followed by a single wash with distilled water and addition of 100 µl/well of chromogenic NBT-BCIP substrate (Pierce Biotech, Rockford, IL). Color was allowed to develop for 10-20 min, until the background was dark. Plates were then rinsed with at least two washes of 300 µl of distilled water, and air dried overnight before reading.

Plate reading: Plates were read on an AID ELHR01 Elispot reader using AID ELISpot Reader v3.1.1. All wells were visually examined, and inappropriate spot counts (lint or other debris) were manually excluded. Data was saved to an Excel worksheet. Duplicate or triplicate wells were averaged, and this number multiplied by 5 to yield the final raw data in spots/million cells.

Quality control: Average viable cell recovery after freeze/thaw exceeded 95%. Runs were repeated if the media control wells averaged more than 20 spots/million, or if the ConA wells were less than 500 spots/million. Also, overall, CD4+ and CD8+ viability, as assessed using flow cytometry with 7-AAD dye exclusion and surface staining, all had to exceed 90% or the run was repeated (data not included).

Table 1A. Experimental regimen for the prime/boost regimen in rhesus monkeys using recombinant adenoviral vectors based on serotype 5 and 35 comprising the gene encoding the CS protein of *P. falciparum*, and the adjuvated RTS,S as the proteinaceous antigen component.

Group	Prime	Month 1	Month 3	Month 6
1	RTS,S	RTS,S	RTS,S	
2	RTS,S	RTS,S	Ad35-CS	
3	Ad35-CS	RTS,S	RTS,S	
4	Ad35-CS		Ad35-CS	
5	Ad35-CS			Ad35-CS
6	Ad5-CS			Ad35-CS
7	Ad35-empty		Ad35-empty	

Table 1B. Blood collection schedule. CBC and cell harvests require whole blood; chemistry and ELISA's require serum. It is assumed that 1 ml of serum represents 2 ml whole blood. Only whole blood volumes are indicated. Ranges indicate where larger samples may be collected from larger monkeys. "0.5" in the CBC/Chem column indicates only CBC performed on those days. * indicates not all monkeys bled at this time point.

Week-Day	CBC/chem	ELISA's	Cells	TOTAL Whole blood (ml)
Week -4 (approx)	1-3	2.5-5	25-35	28-43
Week -1*	1-3	2.5-5		3.5-8
Week0-Day0	1-3	2.5-5		3.5-8
0-1	1-3	2.5		3.5-5.5
0-2	1-3			1-3
0-3	1-3			1-3
1	1-3	2.5-5		3.5-8
2	1-3	2.5-5		3.5-8
4-0	1-3	2.5-5		3.5-8
4-1	1-3	2.5		3.5-5
4-2	1-3			1-3

4-3	1-3			1-3
5	1-3	2.5-5		3.5-8
6	1-3	2.5-5		3.5-8
8	0.5	2.5-5	15-35*	18-40
10	0.5	2.5-5		3-5.5
12-0	1-3	2.5-5		3.5-8
12-1	1-3	2.5		3.5-5.5
12-2	1-3			1-3
12-3	1-3			1-3
13	1-3	2.5-5		3.5-8
14	1-3	2.5-5		3.5-8
15	2.5			2.5
16	1-3	2.5-5	25-35	28-43
18	0.5	2.5-5		3-5.5
20	0.5	2.5-5		3-5.5
22	0.5	2.5-5		3-5.5
25-0	1-3	2.5-5		3-7.5
25-1•	1-5			1-5
25-2•	1-5			1-5
25-3•	1-5			1-5
26	2.5-7.5			1-5
27	0.5	2.5-5	25-35	28-43
28	2.5			2.5
29	0.5	5		5.5
31	0.5	5		5.5
33	0.5	5		5.5
35	0.5	5		5.5
38	0.5	5	25-35*	5.5-43
39	0.5	7		7.5
40*		5-10*	20-35*	25-43*
41*	0.5*	7*		7.5*
44*	0.5*	2.5-5*		3-5.5*
48*	0.5*	5*		5.5*
51*	0.5*	5-10*	25-35*	28-43*
52*	0.5*	5*		5.5*

In the tables below, RTS,S is referred to simply as "RTS".

5 Table 2. PfCS C-terminal-specific T cell immunity two weeks after boost: median and geometric mean IFN- γ ELISpot (in SFU/million cells) and ANOVA comparison. Different prime/boost regimens are given (left).

	2 weeks after boost	
	Median	geo mean
RTS, RTS, RTS	20	31
RTS, RTS, Ad35	233	166
Ad35, RTS, RTS	571	553
Ad35, Ad35 (3 months)	85	78
Ad35, Ad35 (6 months)	47	42
Ad5, Ad35 (6 months)	110	89
Ad35 empty	2	2
ANOVA		P<0.0001

10 Table 3. Student's T-test. p-values for PfCS C-terminal-specific IFN- γ ELISpot comparison, as shown in Table 2, two weeks after boost (last vaccination).

	RTS, RTS, RTS	RTS, RTS, Ad35	Ad35, RTS, RTS	Ad35, Ad35 3 months	Ad35, Ad35 6 months
RTS, RTS, RTS					
RTS, RTS, Ad35	0.05				
Ad35, RTS, RTS	0.008	0.03			
Ad35, Ad35 3 months	0.24	0.20	0.001		
Ad35, Ad35 6 months	0.70	0.015	<0.0001	0.19	
Ad5, Ad35	0.16	0.24	0.0004	0.80	0.07

6 months						
----------	--	--	--	--	--	--

Table 4. C-terminal-specific IFN- γ T cell immunity three months after boost: median and geometric mean ELISpot (in SFU/million cells) and ANOVA comparison. Different prime/boost regimens are given (left).

5

	3 months after boost	
	Median	geo mean
RTS,RTS,RTS	8	9
RTS,RTS,Ad35	35	49
Ad35,RTS,RTS	128	156
Ad35,Ad35 (3 months)	25	25
Ad35,Ad35 (6 months)	15	15
Ad5,Ad35 (6 months)	77	81
Ad35 empty	2	2
ANOVA		P<0.0001

Table 5. Student's T-test. p-values for ELISpot comparison, as shown in Table 4, three months after boost (last vaccination).

10

	RTS,RTS,RTS	RTS,RTS,Ad35	Ad35,RTS,RTS	Ad35,Ad35 3 months	Ad35,Ad35 6 months
RTS,RTS,RTS					
RTS,RTS,Ad35	0.03				
Ad35,RTS,RTS	0.003	0.03			
Ad35,Ad35 3 months	0.15	0.26	0.0009		
Ad35,Ad35 6 months	0.48	0.07	0.0009	0.36	
Ad5,Ad35 6 months	0.006	0.38	0.12	0.04	0.009

Table 6. B cell immunity (anti-repeat antibody titer) two weeks after final boost: median and geometric mean ELISA titer and ANOVA comparison. Different prime/boost regimens are given (left).

5

	2 weeks after boost	
	Median	geo mean
RTS,RTS,RTS	3313	3385
RTS,RTS,Ad35	3705	3400
Ad35,RTS,RTS	1737	2059
Ad35,Ad35 (3 months)	295	336
Ad35,Ad35 (6 months)	161	171
Ad5,Ad35 (6 months)	339	347
Ad35 empty	1	1
ANOVA		P<0.0001

Table 7. Student's T-test. p-values for Antibody comparison, as shown in Table 6, two weeks after final boost (last vaccination).

10

	RTS,RTS,RTS	RTS,RTS,Ad35	Ad35,RTS,RTS	Ad35,Ad35 3 months	Ad35,Ad35 6 months
RTS,RTS,RTS					
RTS,RTS,Ad35	0.99				
Ad35,RTS,RTS	0.07	0.10			
Ad35,Ad35 3 months	< 0.0001	< 0.0001	< 0.0001		
Ad35,Ad35 6 months	< 0.0001	< 0.0001	< 0.0001	0.06	
Ad5,Ad35 6 months	< 0.0001	< 0.0001	0.0002	0.93	0.086

Table 8. B cell immunity (antibody titer) three months after boost related to *P. falciparum* CS: median and geometric mean ELISA (in SFU) and ANOVA comparison. Different prime/boost regimens are given (left).

5

	3 months after boost	
	Median	geo mean
RTS,RTS,RTS	528	521
RTS,RTS,Ad35	487	357
Ad35,RTS,RTS	288	275
Ad35,Ad35 (3 months)	67	78
Ad35,Ad35 (6 months)	70	65
Ad5,Ad35 (6 months)	92	141
Ad35 empty	0	1
ANOVA		P<0.0001

Table 9. Student's T-test. p-values for Antibody comparison, as shown in Table 8, three months after boost (last vaccination).

10

	RTS,RTS,RTS	RTS,RTS,Ad35	Ad35,RTS,RTS	Ad35,Ad35	Ad35,Ad35
RTS,RTS,RTS					
RTS,RTS,Ad35	0.40				
Ad35,RTS,RTS	0.12	0.59			
Ad35,Ad35 3 months	< 0.0001	0.005	0.002		
Ad35,Ad35 6 months	< 0.0001	0.003	0.002	0.32	
Ad5,Ad35 6 months	0.01	0.088	0.17	0.15	0.067

Table 10. Ratio* of geometric means. T- and B cell responses. Ad35 used as a priming vaccine.

	T cell response		B cell response	
	Ratio* (95% conf int) 2 weeks	Ratio* (95% conf int) 3 months	Ratio* (95% conf int) 2 weeks	Ratio* (95% conf int) 3 months
Ad35,RTS,RTS	17.7 (4.4-72.1)	17.8 (5.1-61.9)	0.61 (0.35-0.85)	0.53 (0.23-1.22)
Ad35,Ad35 (3 months)	2.5 (0.5-12.9)	2.9 (0.7-12.5)	0.10 (0.05-0.18)	0.15 (0.08-0.28)
Ad35,Ad35 (6 months)	1.3 (0.3-6.0)	1.7 (0.4-7.9)	0.05 (0.03-0.10)	0.12 (0.07-0.22)

5 * RTS,RTS,RTS as reference

Table 11. Ratio* of geometric means. T- and B cell responses. Ad35 used as a boosting vaccine.

10

	T cell response		B cell response	
	Ratio* (95% conf int) 2 weeks	Ratio* (95% conf int) 3 months	Ratio* (95% conf int) 2 weeks	Ratio* (95% conf int) 3 months
RTS,RTS,Ad35	5.3 (1.0-29.0)	5.6 (1.2-26.1)	1.00 (0.54-1.87)	0.69 (0.27-1.77)
Ad5,Ad35 (6 months)	2.8 (0.6-13.2)	9.2 (2.2-39.0)	0.10 (0.05-0.22)	0.27 (0.11-0.68)

* RTS,RTS,RTS as reference

Table 12. PfCS N-terminal-specific IFN- γ T cell immunity two weeks after final vaccination: median and geometric mean ELISpot (in SFU/million cells) and ANOVA comparison. Different prime/boost regimens are given (left).

5

	2 weeks after boost	
	Median	geo mean
RTS,RTS,RTS	5	4
RTS,RTS,Ad35	17	11
Ad35,RTS,RTS	130	126
Ad35,Ad35 (3 months)	68	78
Ad35,Ad35 (6 months)	108	69
Ad5,Ad35 (6 months)	68	72
Ad35 empty	1	2
ANOVA		P<0.0001

Table 13. Student's T-test. p-values for ELISpot comparison, as shown in Table 12, two weeks after final boost (last vaccination).

10

	RTS,RTS,RTS	RTS,RTS,Ad35	Ad35,RTS,RTS	Ad35,Ad35 3 months	Ad35,Ad35 6 months
RTS,RTS,RTS					
RTS,RTS,Ad35	0.12				
Ad35,RTS,RTS	< 0.0001	0.002			
Ad35,Ad35 3 months	0.0002	0.012	0.39		
Ad35,Ad35 6 months	< 0.0001	0.011	0.23	0.84	
Ad5,Ad35 6 months	< 0.0001	0.007	0.22	0.88	0.94

Table 14. PfCS N-terminal-specific IFN- γ T cell immunity three months after boost: median and geometric mean ELISpot (in SFU/million cells) and ANOVA comparison. Different prime/boost regimens are given (left).

5

	3 months after boost	
	Median	geo mean
RTS,RTS,RTS	3	2
RTS,RTS,Ad35	12	10
Ad35,RTS,RTS	32	40
Ad35,Ad35 (3 months)	25	32
Ad35,Ad35 (6 months)	30	17
Ad5,Ad35 (6 months)	63	55
Ad35 empty	3	2
ANOVA		P<0.0001

Table 15. Student's T-test. p-values for ELISpot comparison, as shown in Table 14, three months after boost (last vaccination).

10

	RTS,RTS,RTS	RTS,RTS,Ad35	Ad35,RTS,RTS		Ad35,Ad35 3 months	Ad35,Ad35 6 months
RTS,RTS,RTS						
RTS,RTS,Ad35	0.035					
Ad35,RTS,RTS	0.0005	0.066				
Ad35,Ad35 3 months	0.0005	0.10	0.73			
Ad35,Ad35 6 months	0.011	0.48	0.27		0.39	
Ad5,Ad35 6 months	< 0.0001	0.01	0.58		0.31	0.08

Table 16. Ratio* of geometric mean T cell response against the N-terminus of PfCS. Ad35CS used as a priming vaccine.

	T cell response	
	Ratio* (95% conf int) 2 weeks	Ratio* (95% conf int) 3 months
Ad35,RTS,RTS	32.4 (12.1-87.2)	16.5 (4.7-58.3)
Ad35,Ad35 (3 months)	20.0 (6.1-66.0)	13.2 (4.1-42.3)
Ad35,Ad35 (6 months)	17.9 (6.5-49.4)	7.1 (1.7-29.3)

5

* RTS,RTS,RTS as reference

10 Table 17. Ratio* of geometric mean T cell response against the N-terminus of CS. Ad35CS used as a boosting vaccine.

	T cell response	
	Ratio* (95% conf int) 2 weeks	Ratio* (95% conf int) 3 months
RTS,RTS,Ad35	2.8 (0.7-10.9)	4.1 (1.1-15.2)
Ad5,Ad35 (6 months)	18.5 (7.4-46.2)	22.4 (9.8-51.1)

15

* RTS,RTS,RTS as reference

REFERENCES

- 5 Bruña-Romero O et al. (2001) Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci USA 98:11491-11496
- 10 Caspers P et al. (1989) The circumsporozoite protein gene from NF54, a Plasmodium falciparum isolate used in malaria vaccine trials. Mol Biochem Parasitol 35:185-189
- Clyde DF et al. (1973) Immunization of men against sporozoite-induced falciparum malaria. Am J Med Sci 266:169-177
- 15 De Jong JC et al. (1999) Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin Microbiol 37:3940-3945
- 20 Doolan DL et al. (1998) DNA vaccination as an approach to malaria control: current status and strategies. Curr Topic Microbiol Immunol 226:37-56
- 25 Estcourt MJ et al. (2002) Prime-boost immunization generates a high frequency, high-avidity CD8+ cytotoxic T lymphocyte population. Int Immunol 14:31-37
- Gandon S et al. (2001) Imperfect vaccines and the evolution of pathogen virulence. Nature 414:751-756
- 30 Gordon DM et al. (1995) Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 171:1576-1585
- 35 Hoffmann SL and Doolan DL. (2000) Malaria vaccines-targeting infected hepatocytes. Nature Med 6:1218-1219
- Horn NA et al. (1995) Cancer Gene Therapy using plasmid DNA: purification of DNA for human clinical trials. Human Gene Therapy 6:565-573
- 40 Kester KE et al. (2001) RTS,S Malaria Vaccine Evaluation Group. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 183:640-647
- 45 Kurtis JD et al. (2001) Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine. Trends in Parasitology 17:219-223
- Lalvani A et al. (1999) Potent induction of focused Th1-type cellular and humoral immune responses by

- RTS,S/SBAS2, a recombinant *Plasmodium falciparum* malaria vaccine. *J Infect Dis* 180:1656-1664
- Lockyer MJ et al. (1989) Wild isolates of *Plasmodium falciparum* show extensive polymorphism in T cell epitopes of the circumsporozoite protein. *Mol Biochem Parasitol* 37:275-280
- 5 Luke TC and Hoffman SL (2003) Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated *Plasmodium falciparum* sporozoite vaccine. *J Exp Biol* 206:3803-3808
- 10 Nardin EH et al. (2001) A totally synthetic polyoxime malaria vaccine containing *Plasmodium falciparum* B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types. *J Immunol* 166:481-489
- 15 Mosmann TR and Coffman RL. (1989) TH1 And TH2 cells: different patterns of lymphokine secretion lead to different functional properties. *Ann Rev of Immunol* 7:145-173
- 20 Musti AM et al. (1983) Transcriptional mapping of two yeast genes coding for glyceraldehydes 3-phosphate dehydrogenase isolated by sequence homology with the chicken gene. *Gene* 25:133-143
- Narum DL et al. (2001) Codon optimization of gene fragments encoding *Plasmodium falciparum* merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. *Infect and Immun* 69:7250-7253
- 25 Nussenzweig RS et al. (1967) Protective immunity produced by the injection of X-irradiated sporozoites of *Plasmodium berghei*. *Nature* 216:160-162
- 30 Romero P et al. (1989) Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. *Nature* 341:323-326
- 35 Stoute JA et al. (1997) A preliminary evaluation of a recombinant circumsporozoite protein vaccine against *Plasmodium falciparum* malaria. *N Eng J Med* 336:86-91
- 40 Stoute JA et al. (1998) Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. *J Infect Dis* 178:1139-1144
- Sun PF et al. (2003) Protective immunity induced with malaria vaccine, RTS,S, is linked to *Plasmodium falciparum* circumsporozoite protein-specific CD4(+) and CD8(+) T cells producing IFN-gamma. *J Immunol* 171:6961-6967
- 45 Valenzuela P et al. (1979) Nucleotide sequence of the gene coding for the major protein of hepatitis B virus surface antigen. *Nature* 280:815-819
- 50 Vogels R et al. (2003) Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell interaction and

bypass of pre-existing adenovirus immunity. J Virol
77:8263

- Wang R et al. (2001) Induction of CD4+ T cell-dependent
CD8+ type 1 responses in humans by a malaria DNA
5 vaccine. Proc Natl Acad Sci USA 98:10817-10822
- Zevering Y et al. (1994) Effect of polymorphism of
sporozoite antigens on T-cell activation. Res
Immunol 145:469-476

CLAIMS

1. A kit of parts comprising:
 - a replication-defective recombinant adenovirus in a pharmaceutically acceptable excipient, said
5 adenovirus comprising a heterologous nucleic acid encoding a circumsporozoite (CS) antigen from a malaria-causing parasite; and
 - an adjuvated proteinaceous antigen;
- 10 wherein said recombinant adenovirus is selected from the group consisting of human adenovirus serotype 11, 24, 26, 34, 35, 48, 49 and 50.

2. A kit of parts according to claim 1, wherein said
15 recombinant adenovirus is human adenovirus serotype 35.

3. A kit of parts according to claim 1 or 2, wherein said proteinaceous antigen comprises a CS protein, or an immunogenic fragment thereof, from a malaria-causing
20 parasite.

4. A kit of parts according to claim 3, wherein said proteinaceous antigen comprises a hybrid protein of CS protein or an immunogenic fragment thereof fused to the
25 surface antigen from hepatitis B virus (HBsAg), in the form of lipoprotein particles with HBsAg.

5. A kit of parts according to claim 4 wherein the proteinaceous antigen comprises RTS,S.
- 30
6. A kit of parts according to any one of claims 1-5, wherein said proteinaceous antigen is adjuvated with an adjuvant comprising QS21 and 3D-MPL.

7. A kit of parts according to claim 6, wherein the adjuvant further comprises cholesterol-containing liposomes.
- 5 8. A kit of parts according to any one of claims 1-7, wherein said malaria-causing parasite is *Plasmodium falciparum*.
9. A kit of parts according to any one of claims 1-8,
10 wherein said heterologous nucleic acid is codon-optimized for increased production of the encoded protein in a mammal, preferably a human.
10. A kit of parts according to any one of claims 1-9,
15 wherein said recombinant adenovirus is present in a mixture with an adjuvant.
11. A kit of parts comprising:
- a replication-defective recombinant simian, canine
20 or bovine adenovirus in a pharmaceutically acceptable excipient, said adenovirus comprising a heterologous nucleic acid encoding a codon-optimized circumsporozoite (CS) antigen from *Plasmodium falciparum*; and
 - 25 - an adjuvated proteinaceous antigen comprising RTS,S.
12. A kit of parts according to claim 11, wherein said proteinaceous antigen is adjuvated with an adjuvant comprising QS21 and 3D-MPL.
- 30 13. A kit of parts according to claim 12, wherein the adjuvant further comprises cholesterol-containing liposomes.

14. A kit of parts according to any one of claims 1-13, wherein said replication-defective recombinant adenovirus is a priming composition and said adjuvated proteinaceous antigen is a boosting composition.

5

15. Use of a replication-defective recombinant adenovirus comprising a heterologous nucleic acid encoding a CS antigen from a malaria-causing parasite, and an adjuvated proteinaceous antigen in the manufacture
10 of a medicament for the treatment or prevention of malaria, wherein said recombinant adenovirus is a simian, a canine, a bovine adenovirus or a human adenovirus serotype 11, 24, 26, 34, 35, 48, 49 or 50.

15 16. Use according to claim 15, wherein said replication-defective recombinant adenovirus is used as a priming composition and said adjuvated proteinaceous antigen is used as a boosting composition.

20 17. Use according to claim 15 or 16, wherein said proteinaceous antigen comprises a CS protein, or an immunogenic fragment thereof, from a malaria-causing parasite.

25 18. Use according to any one of claims 15-17, wherein said malaria-causing parasite is *Plasmodium falciparum*.

19. Use according to any one of claims 15-18, wherein said proteinaceous antigen comprises a hybrid protein of
30 CS protein or an immunogenic fragment thereof fused to the surface antigen from hepatitis B virus (HBsAg), in the form of lipoprotein particles with HBsAg.

20. Use according to claim 19, wherein said adjuvated proteinaceous antigen comprises RTS,S.

21. Use according to any one of claims 15-20, wherein
5 said proteinaceous antigen is adjuvated with QS21 and 3D-MPL.

22. Use according to any one of claims 15-21, wherein
10 said heterologous nucleic acid is codon-optimized for increased production of the encoded protein in a mammal, preferably a human.

23. A method of vaccinating a mammal for a malaria infection comprising the steps of:

- 15 - priming said mammal with a replication-defective recombinant adenovirus in a pharmaceutically acceptable excipient, said adenovirus comprising a heterologous nucleic acid encoding a CS antigen from a malaria-causing parasite; and
- 20 - boosting said mammal with an adjuvated proteinaceous antigen comprising a hybrid protein of CS protein or an immunogenic fragment thereof fused to the surface antigen from hepatitis B virus (HBsAg), in the form of lipoprotein particles with HBsAg.

25

24. A method according to claim 23, wherein said proteinaceous antigen comprises RTS,S.

25. A method according to claim 23 or 24, wherein said
30 recombinant adenovirus is a human, a simian, a canine or a bovine adenovirus.

26. A method according to claim 25, wherein said recombinant adenovirus is a human adenovirus selected

from the group consisting of human adenovirus serotype
11, 24, 26, 34, 35, 48, 49 and 50.

27. A method according to any one of claims 23-26,
5 wherein said proteinaceous antigen is adjuvated with QS21
and 3D-MPL.

28. A method according to any one of claims 23-27,
wherein said malaria-causing parasite is *Plasmodium*
10 *falciparum*.

29. A method according to any one of claims 23-28,
wherein said heterologous nucleic acid is codon-optimized
for increased production of the encoded protein in a
15 mammal, preferably a human.

30. A method of vaccinating a mammal for a malaria
infection using a kit of parts according to any one of
claims 1-14.

20

31. A method of vaccinating a mammal for a malaria
infection using a kit of parts according to claim 14,
wherein the boost is followed by one or more subsequent
boosts.

25

Fig.1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11





Fig. 12



INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2005/055209

A. CLASSIFICATION OF SUBJECT MATTER
A61K39/015

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, PAJ, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>STOUTE J A ET AL: "Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine." THE JOURNAL OF INFECTIOUS DISEASES. OCT 1998, vol. 178, no. 4, October 1998 (1998-10), pages 1139-1144, XP008046110 ISSN: 0022-1899 the whole document</p> <p style="text-align: center;">----- -/--</p>	1-31

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

13 March 2006

Date of mailing of the international search report

24/03/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hix, R

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2005/055209

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GARÇON NATHALIE ET AL: "Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant." EXPERT REVIEW OF VACCINES. APR 2003, vol. 2, no. 2, April 2003 (2003-04), pages 231-238, XP008046132 ISSN: 1476-0584 the whole document	1-31
Y	SUN PEIFANG ET AL: "Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma." JOURNAL OF IMMUNOLOGY, vol. 171, no. 12, 15 December 2003 (2003-12-15), pages 6961-6967, XP002325853 ISSN: 0022-1767 the whole document	1-31
Y	STOUTE J A ET AL: "A PRELIMINARY EVALUATION OF A RECOMBINANT CIRCUMSPOROZOITE PROTEIN VACCINE AGAINST PLASMODIUM FALCIPARUM MALARIA" NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, vol. 336, no. 2, 9 January 1997 (1997-01-09), pages 86-91, XP000990284 ISSN: 0028-4793 the whole document	1-31
Y	DOHERTY J F ET AL: "A Phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia" AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, vol. 61, no. 6, December 1999 (1999-12), pages 865-868, XP002325854 ISSN: 0002-9637 the whole document	1-31
	----- -/-- -----	

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>KESTER KENT E ET AL: "Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria" JOURNAL OF INFECTIOUS DISEASES, vol. 183, no. 4, 15 February 2001 (2001-02-15), pages 640-647, XP002325855 ISSN: 0022-1899 the whole document</p>	1-31
Y	<p>SCHWENK ROBERT ET AL: "Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein-based vaccine." PARASITE IMMUNOLOGY (OXFORD), vol. 25, no. 1, January 2003 (2003-01), pages 17-25, XP002325856 ISSN: 0141-9838 the whole document</p>	1-31
Y	<p>WO 93/10152 A (SMITHKLINE BEECHAM BIOLOGICALS S.A) 27 May 1993 (1993-05-27) cited in the application the whole document</p>	1-31
Y	<p>WO 2004/055187 A (CRUCCELL HOLLAND B.V; PAU, MARIA GRAZIA; HOLTERMAN, LENNART; KASPERS, J) 1 July 2004 (2004-07-01) cited in the application the whole document</p>	1-31
A	<p>BRUNA-ROMERO O ET AL: "Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 22, no. 27-28, 9 September 2004 (2004-09-09), pages 3575-3584, XP004526937 ISSN: 0264-410X the whole document</p>	

-/--

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2005/055209

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WALSH DOUGLAS S ET AL: "Safety and immunogenicity of RTS,S+TRAP malaria vaccine, formulated in the AS02A adjuvant system, in infant rhesus monkeys" AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, vol. 70, no. 5, May 2004 (2004-05), pages 499-509, XP008046107 ISSN: 0002-9637 the whole document</p>	
P,X	<p>HEPPNER D G ET AL: "Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research" VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 23, no. 17-18, 18 March 2005 (2005-03-18), pages 2243-2250, XP004777532 ISSN: 0264-410X the whole document</p>	1-31

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2005/055209

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9310152	A	27-05-1993	AT 177755 T	15-04-1999
			AU 1471797 A	12-06-1997
			AU 2927892 A	15-06-1993
			CA 2123612 A1	27-05-1993
			DE 69228698 D1	22-04-1999
			DE 69228698 T2	16-09-1999
			DK 614465 T3	27-09-1999
			EP 0614465 A1	14-09-1994
			ES 2129461 T3	16-06-1999
			GR 3029717 T3	30-06-1999
			HK 1012405 A1	05-05-2000
			JP 7501213 T	09-02-1995
			KR 251505 B1	01-05-2000
			MX 9206574 A1	01-05-1993
			NZ 245114 A	26-07-1995
			PT 101052 A	31-01-1994
			SG 48390 A1	17-04-1998
<hr/>				
WO 2004055187	A	01-07-2004	US 2005265974 A1	01-12-2005
<hr/>				